Patterns and prognostic significance of cutaneous immune-related adverse events in non –small cell lung cancer

Certain cutaneous immune-related adverse events (cirAEs) arising with programmed death-1/ligand-1 (PD-1, PD-L1) blockade may be associated with survival benefit [1,5]. However, whether this benefit persists across all cirAE and cancer subtypes remains unclear, as melanoma patients have been overrepresented in prior work and analyses of confirmed cirAEs by category using robust statistical methodologies have been scant [1 –5]. Since the therapeutic effects of PD-1/PD-L1 therapy hinge upon immune responses in the tumour microenvironment, cancer type could affect the relationship between cirAEs and clinical outcomes, but this factor remains underexplored.

Source: European Journal of Cancer - February 16, 2021 Category: Cancer & Oncology Authors: Leah L. Thompson, Emily R. Nadelmann, Amy E. Blum, Jaewon Yoon, Nicole J. Polyakov, Ruth D. Kagan, Justin F. Gainor, Meghan J. Mooradian, Steven T. Chen Tags: Letter to the Editor Source Type: research